Logo

Gilead and Galapagos' Jyseleca (filgotinib) Receive the CHMP's Positive Opinion for Moderate to Severe Rheumatoid Arthritis

Share this

Gilead and Galapagos' Jyseleca (filgotinib) Receive the CHMP's Positive Opinion for Moderate to Severe Rheumatoid Arthritis

Shots:

  • The CHMP’s positive opinion is based on P-III FINCH and P-II DARWIN programs that included 4-544 RA patient-years of experience with filgotinib. All three FINCH trials involve a broad range of patients that met their 1EPs
  •  In the trials- the drug achieved ACR20/50/70 and DAS28(CRP)<2.6. Moreover- Filgotinib inhibited the progression of structural joint damage assessed by mTSS compared with PBO
  • Across the FINCH and DARWIN trials- filgotinib(qd) demonstrated a clinical safety profile when administered as monothx./ in combination with MTX. The company expects the EC’s decision in Q3’20

  Ref: Businesswire | Image: Pharmashots

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions